Nivolumab,Ipilimumab,pembrolizumab
BMS,merck
[]
ending the #esmo22 presidential-2 session with a masterful discussion by pr. james larkin 
Cancer researcher; Director of GU Cancers @DanaFarber; Prof of Medicine @HarvardMed; ? lover; ??@PanMass
Views are mine.